Press release -

Luer-Jack Lock patent granted - unscrewing with one hand!

The UK Intellectual Property Office granted 2nd of March 2016 the UK patent for Luer-Jack Lock. The patent is the frontrunner for similar filed applications (pending) in all important markets world wide and is a fundamental member of the Luer-Jack patent family, ensuring a very simple one-hand operated release of connections for different fluid transfer applications.

Luer-Jack Lock is a syringe with a threaded locking interface, and where the release of the threaded locking is done using a very simple trigger action.

This will protect the concept of safeguarding high pressure fluid applications, as well as ensuring a very simple one-hand operated release of the connection for different fluid transfer applications.

One-hand release of connections safeguards against accidental contamination of micro critical aseptic parts and facilitates disconnection of contaminated sharps using only one hand. And the concept is compatible with the good, old and omnipresent Luer Slip and Luer Lock connections.

Luer-Jack market entry world wide

ConceptoMed already holds the patent for Luer-Jack Slip and IP protection for both Slip and Lock applications will further fuel the market introduction of Luer-Jack in all markets world wide.

- Obviously, there are some historical implications in this grant. An extremely important luer lock connection concept just got even better. Twisting off tight connections with two-hand operation is quite different from one-hand trigger action - furthermore maintaining full compatibility with the more-than-a-century old luer standard. The Luer-Jack technology may be applied to any friction fit, screw fit connections. Medical is only one such area of application of the technology, where our IP provides coverage. Syringes with Luer-Jack is only the start, says CEO and M.D. Christian Mide.

ConceptoMed is committed to pursuing global distribution, and to offer an innovative addition to the traditional medical disposable syringe worldwide, and are now searching for additional eager-to-grow distribution partners worldwide.

Background

The 6% taper friction fit (luer) connection is the most common connector type used in medical settings. Tapered fittings ensure tight connections by allowing female hubs to bond with male tips by friction fit. The simple design creates a strong hold. It was invented in the 1890's and has been used predominantly in medical settings for over a century.

In 1930, the Luer Lock patent was granted to Mr. Fairleigh Dickinson (founder of Becton, Dickinson & Company) and comprises a combination of the taper friction tip with an internally threaded collar surrounding the tapered tip - to prevent accidental disengagement when used in high pressure applications.

Both traditional luer slip and luer lock applications are disengaged using two hands for the operation - with fingers in close proximity with critical aseptic parts and sharp objects of medical procedures.

Related links

Topics

  • Business enterprise

ConceptoMed is a rising Medtech star with innovative product categories, unique patent protected Medtech technology and strong finances. We develop and commercialize smart Medtech solutions for an international market. Excellence through Simplicity! We are brave, curious, dedicated and open-minded. Based in Norway, the team is continuously meeting milestones and expanding its activities for International growth.

For more information on the company and career opportunities, see www.conceptomed.com. Follow us on MyNewsdesk and LinkedIn.

Luer-Jack® and Luer-Jack Lock® are Trademarks owned by ConceptoMed AS.

Contacts

Christian Mide

Press contact CEO +47 95 100720

Related content

LUER-JACK APPROVED FOR SALE & MARKETING IN EUROPE (CE mark)

LUER-JACK APPROVED FOR SALE & MARKETING IN EUROPE (CE mark) FIRST ORDERS OF LUER-JACK SHIPPING AFTER CE-MARK APPROVAL ConceptoMed today announced that the company has received CE Mark approval for the Luer-Jack® syringe, a new and innovative medical syringe. Luer-Jack® is now ready for the European market and other large markets, where the CE mark allows for market entry.

US Patent issued for Luer-Jack®

On the 10th of May 2016, the United States Patent and Trademark office issued an official document granting the US patent for Luer-Jack. The US Luer-Jack patent is an important part of the families of similar filed applications in all important markets world wide, and is a fundamental member of the Luer-Jack patent family.

ConceptoMed named in Disrupt 100 - Index of Disruptive Businesses Worldwide

ConceptoMed proudly announce being named in the Disrupt 100 - a bi-annual Tällt Ventures publication celebrating the businesses with the most potential to influence, change or create new global markets. ConceptoMed were selected from over 1 million global startups and corporate ventures and judged by a selection of global brands.

European and Australian Patent Issued for Luer-Jack

On the 31st of August 2016, the European Patent Office issued an official document granting the European patent for Luer-Jack. IP Australia, the Australian Government agency that administers intellectual property (IP) rights and legislation relating to patents, issued an official document granting the Australian patent for Luer-Jack - also on the 31st of August 2016.

Chinese Patent issued for LuerJack

On the 14th of February 2017, the Chinese Patent and Trademark office issued an official document granting the Chinese patent for LuerJack. ConceptoMed’s strategy to protect our intellectual property rights (IPR) remains unchanged and strong. Along with other markets already protected, such as Europe, the US, Australia and Mexico, protection in Asia is now following.

ConceptoMed named "Company of the Year 2016" of Norwegian Medtech Cluster

On Thursday 8th of December 2016, ConceptoMed was named Company of the Year 2016 among approx 190 members of Oslo Medtech, a health technology cluster dedicated to accelerate and support the development of new medtech and eHealth products, services and innovative solutions for the Norwegian and global health care market.